Trial Profile
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jan 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
- Indications Amyloid light-chain amyloidosis; Multiple myeloma; Plasmacytoma
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2023 Planned End Date changed from 22 Oct 2023 to 22 Oct 2024.
- 11 Jan 2022 Planned End Date changed from 22 Oct 2022 to 22 Oct 2023.
- 11 Jan 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.